Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Results from the Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers

Xiaoshu Dai Gurov, Elizabeth Merica, Varsha Iyer, Annie Claeys, Spurthi Patil, Rolandas Urbstonaitis, James Xiao, Michael U. Callaghan

Blood (2022) 140 (Supplement 1): 5426–5427.

https://doi.org/10.1182/blood-2022-157719

Published: 2022

Journal Articles

Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers

Varsha Iyer, Elizabeth Merica, Sebastien Ronseaux, Tressa Gamache, Nancy J. Mulrow, Anja Belcijan, Michael U. Callaghan

Blood (2021) 138 (Supplement 1): 2043.

https://doi.org/10.1182/blood-2021-148381

Published: 2021

Journal Articles

Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors with or without Prophylactic Treatment

Tammuella Chrisentery-Singleton, W Allan Alexander, Ahmad Al-Sabbagh, Daniel Bonzo, Michael U. Callaghan, Miguel A. Escobar, Adam Giermasz, Nikki Hirsh, Janna Journeycake, Sonia Nasr, Doris V. Quon, Michael Recht

Blood (2021) 138 (Supplement 1): 3201.

https://doi.org/10.1182/blood-2021-146247

Published: 2021

Journal Articles

Trial in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase Ib CROSSWALK-a Trial Evaluating the Safety of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOEs) in Patients with Sickle Cell Disease (SCD)

Pablo Bartolucci, Kenneth I. Ataga, Michael U. Callaghan, Lucia De Franceschi, Caterina Minniti, Ari Alexandrou, Diane-Charlotte Imbs, Richard Fox, Himika Patel, Alexandre Sostelly, Jonathan Schimmel

Blood (2021) 138 (Supplement 1): 3108.

https://doi.org/10.1182/blood-2021-147854

Published: 2021

Journal Articles

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Blood (2021) 137 (16): 2231–2242.

https://doi.org/10.1182/blood.2020009217

Published: 2021

Includes: Supplemental data

Journal Articles

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers

Debra D. Pittman, Patrick C. Hines, David Beidler, Denis Rybin, Andrew L. Frelinger, III, Alan D. Michelson, Ke Liu, Xiufeng Gao, Jennell White, Ahmar U. Zaidi, Robert J. Charnigo, Michael U. Callaghan

Blood (2021) 137 (15): 2010–2020.

https://doi.org/10.1182/blood.2020006020

Published: 2021

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-137438

Published: 2020

Journal Articles

Real World Evidence of Prescription Patterns and Effect of Oxbryta (voxelotor) for Patients with Sickle Cell Disease

Nirmish Shah, MD, Ahmar Urooj Zaidi, MD, Michael U. Callaghan, MD, Darla Liles, MD, Clarissa E. Johnson, MD, Laura M De Castro, MD MHSc

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-143434

Published: 2020

Journal Articles

In Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Α Plasma with and without Inhibitors

Steven W. Pipe, MD, Michael Recht, MD PhD, Michael U. Callaghan, MD, Robert F. Sidonio, Jr., MDMSc, Jerry Grandoni, PhD, Veronique Duretz, Daniel Bonzo, PhD, Jean Luc Plantier, PhD, Sean Evans, PhD RPh, Ian S Mitchell, PhD, Cedric Hermans, MDMRCP,PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-136430

Published: 2020

Journal Articles

Sickle Cell Pain: Intervention with Capsaicin Exposure (SPICE)

Alexander Glaros, MD, Michael U. Callaghan, MD, Ahmar Urooj Zaidi, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-143276

Published: 2020

Journal Articles

Validation of Patient-Reported Vaso-Occlusive Crisis Day As a Potential Endpoint in Studies of Sickle Cell Disease

Karin Coyne, PhD, Brooke Currie, Michael U. Callaghan, MD, Kathleen W. Wyrwich, PhD, Sheryl Pease, MBA, Christine L. Baker, JD, MPH, Steven Arkin, MD, Debra D. Pittman, PhD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-137464

Published: 2020

Journal Articles

Hemolytic Biomarkers Predict Adhesiveness of Sickle Blood Cells in a Clinical Adhesion Bioassay

Jennell White, PhD, Xiufeng Gao, MD, Michael Tarasev, Michael.tarasev@functionalfluidics.com, Ke Liu, PhD, Michael U. Callaghan, MD, Patrick C. Hines, MDPhD

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-143402

Published: 2020

Journal Articles

Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study

Michael U. Callaghan, MD, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse-Jarres, Victor Jimenez-Yuste, Midori Shima, MD PhD, Peter Trask, Christine L. Kempton, Craig M. Kessler, Gallia G. Levy, Elena Santagostino

Blood (2018) 132 (Supplement 1): 383.

https://doi.org/10.1182/blood-2018-99-118160

Published: 2018

Journal Articles

Longitudinal Evaluation of a Standardized P-Selectin Flow Adhesion Bioassay: Potential Role for the Assessment and Prediction of Vaso-Occlusive Episodes in Sickle Cell Disease

Ke Liu, PhD, Xiufeng Gao, MD, Jennell White, PhD, Michael U. Callaghan, MD, Patrick C. Hines, MD PhD

Blood (2018) 132 (Supplement 1): 1096.

https://doi.org/10.1182/blood-2018-99-120084

Published: 2018

Journal Articles

A Longitudinal Study to Identify and Assess Adhesion Indices during Vaso-Occlusive Crises in Adults and Adolescents with Sickle Cell Disease

Jennell White, PhD, Xiufeng Gao, MD, Ke Liu, PhD, Michael U. Callaghan, MD, Patrick C. Hines, MD PhD

Blood (2018) 132 (Supplement 1): 1097.

https://doi.org/10.1182/blood-2018-99-120311

Published: 2018

Journal Articles

Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis

Karen L. Zimowski, MD, Glaivy M. Batsuli, MD, Mark T. Reding, MD, Jatin Rana, MD, Michael U. Callaghan, MD, Kelly Tickle, MSN, APN, PPCNP-BC, Shannon L. Meeks, MD, Robert F. Sidonio, Jr., MD

Blood (2018) 132 (Supplement 1): 635.

https://doi.org/10.1182/blood-2018-99-115089

Published: 2018

Journal Articles

Novel therapeutics for hemophilia and other bleeding disorders

Michael U. Callaghan, Robert Sidonio, Steven W. Pipe

Blood (2018) 132 (1): 23–30.

https://doi.org/10.1182/blood-2017-09-743385

Published: 2018

Journal Articles

Defining Vaso-Occlusive Crises in Sickle Cell Disease from the Perspective of the Patient: Development of a New Toolbox to Measure Treatment Outcomes

Andreas M Pleil, PhD, Alexandra Barsdorf, PhD, Michael U. Callaghan, Karin Coyne, PhD, Katy Benjamin, PhD, David Beidler, PhD, Robert J Charnigo, MS

Blood (2017) 130 (Supplement 1): 3415.

https://doi.org/10.1182/blood.V130.Suppl_1.3415.3415

Published: 2017

Journal Articles

Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study

Maria Elisa Mancuso, Michael U. Callaghan, Rebecca Kruse-Jarres, Christine L Kempton, Jin Xu, Olivier Catalani, Elina Asikanius, Gallia G. Levy, Midori Shima, MDPhD, Guy Young, Johannes Oldenburg

Blood (2017) 130 (Supplement 1): 1071.

https://doi.org/10.1182/blood.V130.Suppl_1.1071.1071

Published: 2017

Journal Articles

Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study

Michael U. Callaghan, Claude Negrier, Guy Young, Liane Khoo, Johnny Mahlangu, Jerzy Windyga, Johannes Oldenburg, Jin Xu, Olivier Catalani, Elina Asikanius, Joanne I. Adamkewicz, Midori Shima, MDPhD

Blood (2017) 130 (Supplement 1): 3668.

https://doi.org/10.1182/blood.V130.Suppl_1.3668.3668

Published: 2017

NARROW

Results from the Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers

Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers

Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors with or without Prophylactic Treatment

Trial in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase Ib CROSSWALK-a Trial Evaluating the Safety of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOEs) in Patients with Sickle Cell Disease (SCD)

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers

Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)

Real World Evidence of Prescription Patterns and Effect of Oxbryta (voxelotor) for Patients with Sickle Cell Disease

In Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Α Plasma with and without Inhibitors

Sickle Cell Pain: Intervention with Capsaicin Exposure (SPICE)

Validation of Patient-Reported Vaso-Occlusive Crisis Day As a Potential Endpoint in Studies of Sickle Cell Disease

Hemolytic Biomarkers Predict Adhesiveness of Sickle Blood Cells in a Clinical Adhesion Bioassay

Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study

Longitudinal Evaluation of a Standardized P-Selectin Flow Adhesion Bioassay: Potential Role for the Assessment and Prediction of Vaso-Occlusive Episodes in Sickle Cell Disease

A Longitudinal Study to Identify and Assess Adhesion Indices during Vaso-Occlusive Crises in Adults and Adolescents with Sickle Cell Disease

Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis

Novel therapeutics for hemophilia and other bleeding disorders

Defining Vaso-Occlusive Crises in Sickle Cell Disease from the Perspective of the Patient: Development of a New Toolbox to Measure Treatment Outcomes

Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study

Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only